An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain.

Mult Scler

Multiple Sclerosis Unit, Institute of Biomedical Investigation, University Hospital of Bellvitge, Faculty of Medicine, Campus Bellvitge, University of Barcelona, Spain.

Published: July 2007

Multiple sclerosis (MS) is a chronic demyelinating disease, which represents a great economic burden to society. Cost-of-illness studies of MS tend to underestimate the intangible costs related to pain, anxiety and helplessness. The purpose of this study was to estimate the intangible costs of MS, and determine whether these costs increase as disability progresses. We studied 211 consecutive patients with MS who attended our MS unit. Patients mean age was 41.6 (SD: 10.7) years, 69% were female, and their mean Expanded Disability Status Scale (EDSS) score was 2.47 (SD: 2.05). Quality-of-life was measured with the EuroQoL visual analogue scale. Quality-adjusted life year (QALY) was calculated for each patient. Patients were grouped into five disability stages according to their EDSS, and QALY was compared between patients and a group of healthy controls matched by age and sex. A benchmark value was ascribed to each QALY lost, and the intangible costs per patient-year were calculated as Euros 0 (EDSS =0), Euros 1100 (EDSS =1-3), Euros 8250 (EDSS =3.5-5.5), Euros 9900 (EDSS =6-7) and Euros 11,000 (EDSS >7.5). Sensitivity analysis showed a similar progression of costs. We conclude that intangible costs are relevant in MS, especially when disability increases. Although the method to calculate the costs remains controversial, we consider that they should be included in cost analysis of MS.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458506073480DOI Listing

Publication Analysis

Top Keywords

intangible costs
20
costs
8
multiple sclerosis
8
edss
7
intangible
5
disability
5
euros
5
approach estimating
4
estimating intangible
4
costs multiple
4

Similar Publications

Objective: To compare the cost-effectiveness of a gestational carrier to a uterine transplantation in the treatment of absolute uterine-factor infertility.

Design: We performed a cost-effectiveness analysis using a decision-tree mathematical model comparing a gestational carrier to a uterine transplantation.

Subjects: Published literature was used to derive costs for solid organ transplant, immunosuppression, gestational carrier obtainment, in vitro fertilization, preimplantation genetic testing, and frozen embryo transfer.

View Article and Find Full Text PDF

The purpose of this paper is to describe the protocol for the evaluation of programs offered by the Satellite Foundation, designed for, and with, children and young people aged between 8 and 25 years who have family members experiencing mental health challenges. To achieve this, the Social Return on Investment (SROI) method was chosen. SROI is an economic measurement tool used to apply a monetary value to socially situated outcomes.

View Article and Find Full Text PDF

Purpose: This study evaluates the Social Return on Investment (SROI) of implementing measures to prevent fragility fractures in postmenopausal women with osteoporosis (OP) in Spain.

Methods: A group of 13 stakeholders identified necessary actions for improving refracture prevention and assessed the investment required from the Spanish National Health System (SNHS), considering direct, indirect, and intangible costs over a one-year period. Unitary costs were sourced from scientific literature and official data, and intangible costs were estimated through surveys on women's willingness to pay for better health-related quality of life.

View Article and Find Full Text PDF

Extreme heat represents a major health risk for the world's population, that is amplified by climate change. However, the health costs associated with these heat events have only been little studied. To stimulate the implementation of effective interventions against extreme heat, a more comprehensive economic valuation of these health impacts is crucial.

View Article and Find Full Text PDF

Prior to measles vaccine introduction in 1963, measles virus caused hundreds of thousands of annual reported cases, which led to substantial US morbidity, mortality, and costs. Similarly, congenital rubella syndrome (CRS) led to highly visible and tragic lifelong disability for thousands of Americans, before rubella vaccine introduction in 1969. The US certified national virus transmission elimination of indigenous measles in 2000 and rubella in 2004.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!